<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885662</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-A-J307</org_study_id>
    <nct_id>NCT02885662</nct_id>
  </id_info>
  <brief_title>Study of CS-3150 in Patients With Primary Aldosteronism</brief_title>
  <official_title>A Study of CS-3150 to Evaluate Efficacy and Safety in Patients With Primary Aldosteronism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine antihypertensive effect and safety of CS-3150 in patients with primary
      aldosteronism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">July 20, 2017</completion_date>
  <primary_completion_date type="Actual">July 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitting blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Change from baseline in sitting systolic and diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of sitting blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Time course of sitting systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving sitting blood pressure goal</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>CS-3150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <description>CS-3150 2.5 to 5.0 mg , orally.</description>
    <arm_group_label>CS-3150</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 20 years or older at informed consent

          -  Patients diagnosed primary aldosteronism by screening test of plasma aldosterone
             concentration (PAC) and aldosterone to renin ratio (ARR), and confirmatory testing

          -  Patients satisfying following blood pressure;

               -  sitting systolic blood pressure (SBP) ≥ 140 mmHg and &lt;180 mmHg

               -  sitting diastolic blood pressure (DBP) ≥ 90 mmHg and &lt;110 mmHg

        Exclusion Criteria:

          -  Secondary hypertension except primary aldosteronism or hypertensive emergency

          -  Patients diagnosed diabetic nephropathy

          -  Patients with type 1 diabetes

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2

          -  Serum potassium level &lt; 3.0 or ≥ 5.1 milliequivalent (mEq)/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan Organaization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary aldosteronism</keyword>
  <keyword>Hypertension</keyword>
  <keyword>mineralocorticoid receptor antagonist</keyword>
  <keyword>Developmental Phase III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

